- Home
- STIM vs ACRS Comparison
STIM vs ACRS Comparison
Compare STIM & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STIM
- ACRS
- Stock Information
- Founded
- STIM 2003
- ACRS 2012
- Country
- STIM United States
- ACRS United States
- Employees
- STIM N/A
- ACRS N/A
- Industry
- STIM Medical/Dental Instruments
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- STIM Health Care
- ACRS Health Care
- Exchange
- STIM Nasdaq
- ACRS Nasdaq
- Market Cap
- STIM 224.8M
- ACRS 198.2M
- IPO Year
- STIM 2018
- ACRS 2015
- Fundamental
- Price
- STIM $2.73
- ACRS $2.02
- Analyst Decision
- STIM Strong Buy
- ACRS Strong Buy
- Analyst Count
- STIM 2
- ACRS 9
- Target Price
- STIM $7.00
- ACRS $9.25
- AVG Volume (30 Days)
- STIM 1.1M
- ACRS 1.0M
- Earning Date
- STIM 11-11-2025
- ACRS 11-05-2025
- Dividend Yield
- STIM N/A
- ACRS N/A
- EPS Growth
- STIM N/A
- ACRS N/A
- EPS
- STIM N/A
- ACRS N/A
- Revenue
- STIM $111,106,000.00
- ACRS $16,789,000.00
- Revenue This Year
- STIM $105.70
- ACRS N/A
- Revenue Next Year
- STIM $11.77
- ACRS $7.02
- P/E Ratio
- STIM N/A
- ACRS N/A
- Revenue Growth
- STIM 54.17
- ACRS N/A
- 52 Week Low
- STIM $0.52
- ACRS $1.05
- 52 Week High
- STIM $5.92
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- STIM 40.26
- ACRS 56.93
- Support Level
- STIM $2.65
- ACRS $1.88
- Resistance Level
- STIM $3.21
- ACRS $2.10
- Average True Range (ATR)
- STIM 0.20
- ACRS 0.11
- MACD
- STIM 0.02
- ACRS 0.01
- Stochastic Oscillator
- STIM 12.70
- ACRS 80.52
About STIM Neuronetics Inc.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.